[Vascular endothelial growth factor (VEGF) production by a dopamine D2 receptor agonist and its action mechanism in glioma cells].
Mayuzumi
Takeyasu
T
Graduate School of Medicine, Hokkaido University.
D015152:Blotting, Northern; D015153:Blotting, Western; D001971:Bromocriptine / Q000494:pharmacology*; D015687:Cell Hypoxia / Q000502:physiology; D004797:Enzyme-Linked Immunosorbent Assay; D005910:Glioma / Q000378:metabolism*; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D008156:Luciferases; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014157:Transcription Factors / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*
C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D012333:RNA, Messenger; D017448:Receptors, Dopamine D2; D014157:Transcription Factors; D042461:Vascular Endothelial Growth Factor A; D001971:Bromocriptine; D008156:Luciferases